 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
104 News |  |
| «12 |
- |||||||||| atabecestat (JNJ-54861911) / J&J
New P2/3 trial: An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (clinicaltrials.gov) - Oct 6, 2015
P2/3, N=1650, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- atabecestat (JNJ-54861911) / J&J
Enrollment closed: Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia (clinicaltrials.gov) - Aug 20, 2015
P1, N=18, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting
- |||| atabecestat (JNJ-54861911) / J&J
Enrollment open: An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum (clinicaltrials.gov) - Aug 1, 2015
P2, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
Trial completion: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jun 25, 2015
P1, N=45, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| atabecestat (JNJ-54861911) / J&J
New P2 trial: An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum (clinicaltrials.gov) - Apr 1, 2015
P2, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- atabecestat (JNJ-54861911) / J&J
Enrollment open: Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia (clinicaltrials.gov) - Apr 1, 2015
P1, N=18, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
Trial completion, Enrollment closed: A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants (clinicaltrials.gov) - Mar 25, 2015
P1, N=12, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- atabecestat (JNJ-54861911) / J&J
Enrollment closed: A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants (clinicaltrials.gov) - Mar 14, 2015
P1, N=12, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia (clinicaltrials.gov) - Feb 10, 2015
P1, N=18, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants (clinicaltrials.gov) - Feb 5, 2015
P1, N=12, Recruiting, Sponsor: Janssen Research & Development, LLC
- atabecestat (JNJ-54861911) / J&J
Trial primary completion date: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jan 30, 2015
P1, N=48, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Apr 2015
- |||| atabecestat (JNJ-54861911) / J&J
Enrollment open: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Jan 7, 2015
P2, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Dec 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- ||| atabecestat (JNJ-54861911) / J&J
Trial completion: A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants (clinicaltrials.gov) - Nov 24, 2014
P1, N=64, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- | atabecestat (JNJ-54861911) / J&J
Trial completion: A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates (clinicaltrials.gov) - Nov 23, 2014
P1, N=16, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- atabecestat (JNJ-54861911) / J&J
Enrollment closed: A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates (clinicaltrials.gov) - Nov 17, 2014
P1, N=16, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- atabecestat (JNJ-54861911) / J&J
Enrollment open: A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates (clinicaltrials.gov) - Oct 17, 2014
P1, N=16, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
Trial completion, Enrollment change: A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants (clinicaltrials.gov) - Oct 17, 2014
P1, N=13, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed | N=30 --> 13
- ||||| atabecestat (JNJ-54861911) / J&J
New P2 trial: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (clinicaltrials.gov) - Oct 10, 2014
P2, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants (clinicaltrials.gov) - Oct 10, 2014
P1, N=12, Completed, Sponsor: Janssen Research & Development, LLC
- | atabecestat (JNJ-54861911) / J&J
Trial completion: A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants (clinicaltrials.gov) - Sep 12, 2014
P1, N=24, Completed, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed | N=30 --> 13 Recruiting --> Completed
- atabecestat (JNJ-54861911) / J&J
Trial primary completion date: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Sep 10, 2014
P1, N=48, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial primary completion date: Aug 2014 --> Dec 2014
- atabecestat (JNJ-54861911) / J&J
Enrollment open: A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants (clinicaltrials.gov) - Aug 15, 2014
P1, N=30, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates (clinicaltrials.gov) - Aug 7, 2014
P1, N=16, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| atabecestat (JNJ-54861911) / J&J
Enrollment open: A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants (clinicaltrials.gov) - Aug 5, 2014
P1, N=64, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants (clinicaltrials.gov) - Jul 23, 2014
P1, N=30, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- atabecestat (JNJ-54861911) / J&J
Enrollment open: A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants (clinicaltrials.gov) - Jul 8, 2014
P1, N=24, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants (clinicaltrials.gov) - Jul 2, 2014
P1, N=24, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- atabecestat (JNJ-54861911) / J&J
Enrollment change: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jul 1, 2014
P1, N=48, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=24 --> 48
- ||| atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants (clinicaltrials.gov) - May 29, 2014
P1, N=64, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| atabecestat (JNJ-54861911) / J&J
Trial completion: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants (clinicaltrials.gov) - Jan 12, 2014
P1, N=70, Completed, Sponsor: Janssen Research & Development, LLC
N=24 --> 48 Recruiting --> Completed
- atabecestat (JNJ-54861911) / J&J
Enrollment open: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Jan 9, 2014
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- | atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (clinicaltrials.gov) - Nov 5, 2013
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||| atabecestat (JNJ-54861911) / J&J
Trial completion: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo (clinicaltrials.gov) - Sep 9, 2013
P1, N=56, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants (clinicaltrials.gov) - Jun 25, 2013
P1, N=70, Completed, Sponsor: Janssen Research & Development, LLC
- ||| atabecestat (JNJ-54861911) / J&J
New P1 trial: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo (clinicaltrials.gov) - Apr 8, 2013
P1, N=56, Completed, Sponsor: Janssen Research & Development, LLC